Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1716550 | 1.00 | TBXAS1 (0.53) | TBXAS1PPARGPPARAPTGS1PTGS2 | |
| SCHEMBL12696346 | 1.00 | TBXAS1 (0.53) | TBXAS1PPARGPPARAPTGS1PTGS2 | |
| SCHEMBL11237591 | 0.91 | TBXAS1 (0.59) | TBXAS1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL19553694 | 0.85 | PTGS1 (0.66) | TBXAS1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL11615201 | 0.85 | ACACB (0.47) | PPARGPPARAPTGS1PTGS2LMNA | |
| SCHEMBL15147780 | 0.85 | MME (0.46) | TBXAS1PPARGPPARAPTGS1PTGS2 | |
| SCHEMBL22184250 | 0.85 | MME (0.46) | TBXAS1PPARGPPARAPTGS1PTGS2 | |
| SCHEMBL1410416 | 0.83 | TBXAS1 (0.53) | TBXAS1PPARGPPARAPTGS1PTGS2 | |
| SCHEMBL11996333 | 0.83 | TBXAS1 (0.53) | TBXAS1PPARGPPARAPTGS1PTGS2 | |
| SCHEMBL18698817 | 0.83 | ACACB (0.50) | PPARGPPARAPTGS1PTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
| WO-2014085575-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-8466291-B2 | 1,5-dideoxy-1,5-imino-D-glucitol compounds | ACADEMIA SINICA (TW) | 2013-06-18 | — | — | US | disclosed |
| WO-2012129564-A2 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-8110596-B2 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010045598-A2 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | WO | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090216028-A1 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| WO-2009026177-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | TPO, FLI1, SSTR3 | TBXAS1 3294/4885PPARG 776/4885PPARA 1844/4885 |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | TBXAS1 356/4885PPARG 232/4885PPARA 896/4885 |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | TPO, FLI1, SSTR3 | TBXAS1 3294/4885PPARG 776/4885PPARA 1844/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TBXAS1 2241/4885PPARG 4598/4885PPARA 4050/4885 |
| US-20090216028-A1 | Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer | PLAT, F2R, F12 | TBXAS1 15/4885PPARG 884/4885PPARA 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.